Found: 1
Select item for more details and to access through your institution.
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status.
- Published in:
- Cancer Medicine, 2017, v. 6, n. 8, p. 1904, doi. 10.1002/cam4.1140
- By:
- Publication type:
- Article